DiaSorin (OTCMKTS:DSRLF – Get Free Report) is expected to be announcing its resultson Friday, July 31st. Analysts expect the company to announce earnings of $1.12 per share and revenue of $357.7870 million for the quarter.
DiaSorin Stock Performance
OTCMKTS DSRLF opened at $81.00 on Thursday. The business has a fifty day moving average price of $78.09 and a two-hundred day moving average price of $76.58. DiaSorin has a fifty-two week low of $66.50 and a fifty-two week high of $100.00.
Analyst Ratings Changes
Several brokerages recently weighed in on DSRLF. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Piper Sandler initiated coverage on shares of DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating on the stock. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.
About DiaSorin
DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.
Read More
- Five stocks we like better than DiaSorin
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
